Constipation is an unsatisfactory defecation distinguished by difficult stool passage, infrequent stools or both.
Difficult stool passage may include straining, feeling of difficulty in passing stool, incomplete evacuation, lumpy/hard stools, prolonged time to defecate, need for manual maneuver to pass stool, abdominal discomfort and feeling of anorectal blockade.
Chronic constipation is considered when symptoms of constipation have existed ≥3 months.
Symptoms of chronic constipation may be due to dysfunction of intestinal motility, visceral sensitivity, anorectal musculature or the enteric nervous system.
Use of plecanatide in the treatment of chronic idiopathic constipation appears to induce notable improvements in bowel movement frequency, stool consistency, and straining and abdominal symptoms, with a low incidence of adverse events, according to the results of a phase III trial.
Absenteeism among patients with chronic constipation appear to have a stronger association with depression than symptom severity, according to a recent study, suggesting that a portion of the indirect costs of chronic constipation is attributable to depression.
Prucalopride elicits more high amplitude propagating contractions compared with PEG3350 in the 12-hour period following treatment among patients with chronic constipation, a randomised, cross-over, reader-blinded study has shown.
Rebamipide reduces atypical gastrointestinal (GI) symptoms, including gastroesophageal reflux, gastroparesis, peptic ulcer, and constipation, in patients with type 2 diabetes mellitus (T2DM), according to an investigator-initiated clinical trial.
Peripheral μ-opioid receptor antagonist (PAMORA) methylnaltrexone (MNTX), naloxegol and lubiprostone are promising treatment options for opioid-induced constipation in patients with chronic noncancer pain, based on a review.
Patients infected with Helicobacter pylori strains derived from different geographical human ancestries than their own are likely to develop more severe symptoms which include gastric cancers, says an expert.
Having both type 1 diabetes and coeliac disease (CD) autoimmunity in early childhood appears to be more common than expected, with the development of islet autoantibodies (IAs) conferring a significant risk of subsequent tissue transglutaminase autoantibodies (tTGAs), according to data from the TEDDY* study.